Signal active
Bio
Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.
Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.
Robert serves on the Board of Directors of Caribou Biosciences, Plasmagen Biosciences, Tempest Therapeutics, Trivitron Healthcare, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Laurus Labs (NSE:LAURUSLABS), Surface Oncology, Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), and ViewRay (NASDAQ:VRAY).
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
1946
456
115
91
11-50
Financial Services, Venture Capital, Finance, Business Development
Jobs history
2
RareCyte
Board Member
Invalid date - Current
Affinia Therapeutics
Board Member
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Robert Weisskoff is the Partner at F-Prime Capital, based in United States, North America. With a background in Financial Services, Robert Weisskoff has a rich history of leadership and innovation. Robert Weisskoff studied Ph.D Physics @ Massachusetts Institute of Technology. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
7
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
May 03, 2021 | Affinia Therapeutics | Series B - Affinia Therapeutics | F-Prime Capital | 110.0M |
Jun 23, 2021 | Adela | Series A - Adela | F-Prime Capital | 60.0M |
Sep 09, 2021 | RareCyte | Series G - RareCyte | F-Prime Capital | 24.0M |
Dec 12, 2023 | Shinobi Therapeutics | Series A - Shinobi Therapeutics | F-Prime Capital | 51.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.